United Therapeutics Corp (UTHR) 148.37 $UTHR
SteadyMed Reports Recent Developments and Third Quarter 2015 Financial Results
GlobeNewswire - Thu Nov 12, 3:10PM CST
SteadyMed Ltd. (Nasdaq:STDY), a specialty pharmaceutical company focused on the development of drug products to treat orphan and high-value diseases with unmet parenteral delivery needs, today announced recent developments and financial results for the third quarter ended September 30, 2015.
UTHR: 148.37 (+2.38), STDY: 3.63 (+0.06)
Global United Therapeutics Corporation Market to 2015,Analysis,Competitive Strategies and Forecasts,- Acute Market Reports
M2 - Thu Nov 12, 10:33AM CST
Acute Market Reports include new market research report "Global Markets Directs, United Therapeutics Corporation Product Pipeline Review 2015, provides an overview of the United Therapeutics Corporations pharmaceutical research and development focus " to its huge collection of research reports.
UTHR: 148.37 (+2.38)
12.5% Return Seen to Date on SmarTrend United Therapeutics Call (UTHR)
Comtex SmarTrend(R) - Wed Nov 11, 9:39AM CST
SmarTrend identified an Uptrend for United Therapeutics (NASDAQ:UTHR) on October 27th, 2015 at $138.63. In approximately 2 weeks, United Therapeutics has returned 12.53% as of today's recent price of $156.00.
UTHR: 148.37 (+2.38)
United Therapeutics Stock: What is the Social Media Crowd Thinking About UTHR?
Zacks Equity Research - Zacks Investment Research - Wed Nov 11, 5:04AM CST
If you are looking for a stock in the Medical-Drugs industry, United Therapeutics Corporation (UTHR) could be one to watch closely
UTHR: 148.37 (+2.38)
United Therapeutics Corporation Product Pipeline Review 2015
M2 - Tue Nov 10, 3:19AM CST
AcuteMarketReports.com has announced the addition of " United Therapeutics Corporation - Product Pipeline Review - 2015 " Market Research Report to their Database.
UTHR: 148.37 (+2.38)
Gilead and 2 Biotech Picks Value Investors Will Love
Zacks Equity Research - Zacks Investment Research - Fri Nov 06, 4:07PM CST
Don't miss these value biotech stocks for your portfolio.
BIIB: 280.99 (-2.54), ESRX: 84.25 (-0.41), GILD: 104.55 (+0.74), SHPG: 211.23 (+4.22), UTHR: 148.37 (+2.38), AMGN: 158.11 (+3.61), ANIK: 41.66 (-0.17)
Anthrax - Pipeline Review, H2 2015
M2 - Fri Nov 06, 8:26AM CST
Research and Markets (http://www.researchandmarkets.com/research/3bjw94/anthrax) has announced the addition of the "Anthrax - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Anthrax, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Anthrax and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Aduro BioTech, Inc. - Altimmune, Inc. - Aphios Corporation - Aradigm Corporation - Bavarian Nordic A/S - Bristol-Myers Squibb Company - Cellceutix Corporation - ContraFect Corporation - Dynavax Technologies Corporation - Elusys Therapeutics, Inc. - Emergent BioSolutions Inc. - Green Cross Corporation - Grifols, S.A. - Hawaii Biotech, Inc. - iBio, Inc. - Innovative Biologics, Inc. - Microbiotix, Inc. - NanoBio Corporation - Oragenics, Inc. - PaxVax - Pfenex Inc. - PharmAthene, Inc. - Protein Potential, LLC - ProThera Biologics, LLC. - PsiOxus Therapeutics Limited - Soligenix, Inc. - Syntiron LLC - Tetraphase Pharmaceuticals Inc. - United Therapeutics Corporation - VLP Biotech, Inc. For more information visit http://www.researchandmarkets.com/research/3bjw94/anthrax
DVAX: 24.31 (+0.39), TTPH: 10.94 (-0.19), ADRO: 28.77 (+1.14), EBS: 36.60 (+0.63), UTHR: 148.37 (+2.38), BMY: 65.71 (+0.69), PFNX: 13.72 (-0.64), PIP: 1.71 (unch), IBIO: 0.65 (-0.02), OGEN: 1.30 (unch)
United Therapeutics Corporation 2015 - Market Size, Growth, and Forecasts,Acute Market Reports
M2 - Wed Nov 04, 5:07AM CST
Product Synopsis
UTHR: 148.37 (+2.38)
Global Biosimilars Market Report, 2015-2025 - The biosimilar market is projected to be worth USD 32 billion worldwide by 2025
PR Newswire Europe - Tue Nov 03, 11:11AM CST
Research and Markets (http://www.researchandmarkets.com/research/hcv3cc/global [http://www.researchandmarkets.com/research/hcv3cc/global]) has announced the addition of the "Global Biosimilars Market, 2015 - 2025" [http://www.researchandmarkets.com/research/hcv3cc/global] report to their offering.
BIIB: 280.99 (-2.54), UTHR: 148.37 (+2.38), CTIC: 1.10 (-0.02), CHRS: 27.35 (+0.37), JNJ: 101.40 (+0.18), NPSP: 45.97 (+0.01), IBIO: 0.65 (-0.02), EBS: 36.60 (+0.63), SLXP: 172.96 (+0.15), AMGN: 158.09 (+3.59), SPPI: 5.21 (+0.06), LLY: 81.22 (-0.01), GSK: 40.61 (+0.38), ANIK: 41.66 (-0.17), NVO: 53.93 (+0.67), BAX: 37.63 (-0.30), MRK: 53.69 (-0.01), NVS: 87.65 (+0.60)
Bloomberg's "The Year Ahead: 2016" to Feature Apple's Angela Ahrendts, Bank Of America's Brian Moynihan, Credit Suisse's Tidjane Thiam, Fashion Legend Diane von Furstenberg and More
PR Newswire - Mon Nov 02, 8:00AM CST
Bloomberg today announced the third annual "The Year Ahead: 2016" Summit, an intimate gathering of today's most powerful business leaders and industry influencers from around the world on November 9-10th in New York City. Providing forward-looking insight on the industries, companies, products, people, and trends poised to emerge over the course of next year, "The Year Ahead: 2016" is designed to help global executives get ahead of the challenges their businesses will face in the months to come. Speakers include Apple Senior Vice President Angela Ahrendts; Bank of America Chairman and CEO Brian Moynihan; Credit Suisse CEO Tidjane Thiam; BBG Ventures President Susan Lyne; United Therapeutics Chairman and Co-CEO Martine Rothblatt; and Jet.com Founder and CEO Marc Lore.
UTHR: 148.37 (+2.38)
United Therapeutics Beats on Q3 Earnings, Revenues
Arpita Dutt - Zacks Investment Research - Wed Oct 28, 11:18AM CDT
United Therapeutics' (UTHR) third quarter results were better-than-expected with the company's products performing well.
MDT: 76.51 (+0.27), UTHR: 148.37 (+2.38), AMGN: 158.13 (+3.63), EXEL: 5.66 (+0.18)
United Therapeutics (UTHR) Catches Eye: Stock Jumps 8.8%
Zacks Equity Research - Zacks Investment Research - Wed Oct 28, 7:45AM CDT
United Therapeutics Corporation (UTHR) was a big mover last session, as the company saw its shares rise roughly 9% on the day.
LCI: 36.23 (+0.86), UTHR: 148.37 (+2.38)
SmarTrend Watching for Potential Pullback in Shares of United Therapeutics After 8.78% Gain
Comtex SmarTrend(R) - Tue Oct 27, 4:38PM CDT
United Therapeutics (NASDAQ:UTHR) traded in a range yesterday that spanned from a low of $134.27 to a high of $142.98. Yesterday, the shares gained 8.8%, which took the trading range above the 3-day high of $129.90 on volume of 1.9 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
UTHR: 148.37 (+2.38)
United Therapeutics Rises 8.78% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Tue Oct 27, 4:38PM CDT
United Therapeutics (NASDAQ:UTHR) traded in a range yesterday that spanned from a low of $134.27 to a high of $142.98. Yesterday, the shares gained 8.8%, which took the trading range above the 3-day high of $129.90 on volume of 1.9 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
UTHR: 148.37 (+2.38)
UNITED THERAPEUTICS CORP (UTHR) Earnings Report: Q3 2015 Conference Call Transcript
at The Street - Tue Oct 27, 1:46PM CDT
The following UNITED THERAPEUTICS CORP (UTHR) conference call took place on October 27, 2015, 09:00 AM ET. This is a transcript of that earnings call:
UTHR: 148.37 (+2.38)
4 Drugmakers Who Beat Q3 Estimates Tuesday
at Investor's Business Daily - Tue Oct 27, 11:30AM CDT
The battered drug industry got a blast of good news Tuesday morning as three big pharmas and one sizable biotech beat Wall Street's Q3 expectations, sending their stocks up. United Therapeutics (UTHR) was up 11% in midday trading on the stock market...
GILD: 104.55 (+0.74), MRK: 53.69 (-0.01), PFE: 33.05 (-0.11), UTHR: 148.37 (+2.38), ABBV: 60.39 (+0.38), BMY: 65.71 (+0.69)
United Therapeutics tops Street 3Q forecasts
Automated Insights - Tue Oct 27, 5:15AM CDT
SILVER SPRING, Md. (AP) _ United Therapeutics Corp. (UTHR) on Tuesday reported third-quarter net income of $464.4 million, after reporting a loss in the same period a year earlier.
UTHR: 148.37 (+2.38)
United Therapeutics Corporation Reports Third Quarter 2015 Financial Results
PR Newswire - Tue Oct 27, 5:00AM CDT
United Therapeutics Corporation (NASDAQ: UTHR) today announced its financial results for the third quarter ended September 30, 2015.
UTHR: 148.37 (+2.38)
United Therapeutics Has Returned 26.0% Since SmarTrend Recommendation (UTHR)
Comtex SmarTrend(R) - Wed Oct 21, 4:50PM CDT
SmarTrend identified a Downtrend for United Therapeutics (NASDAQ:UTHR) on July 27th, 2015 at $166.73. In approximately 3 months, United Therapeutics has returned 26.02% as of today's recent price of $123.35.
UTHR: 148.37 (+2.38)
Pulmonary Hypertension - Global Market Research 2015-2019 - Increased focus on combination therapies
M2 - Wed Oct 21, 10:01AM CDT
Research and Markets (http://www.researchandmarkets.com/research/4ff5rj/pulmonary) has announced the addition of the "Pulmonary Hypertension - Global Market Research 2015-2019" report to their offering. The global pulmonary hypertension market to grow at a CAGR of 2.92% over the period 2014-2019. The report, Global Pulmonary Hypertension Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. It covers the market size and forecast as well as market segmentation and pipeline landscape. The report includes a discussion of the key vendors operating in this market. The hypertension treatment is shifting toward the use of combination therapies that employ two or more drugs. Combination therapy with separate agents or a fixed-dose combination pill offers the potential to lower blood pressure at a faster pace, help in obtaining target blood pressure, and decrease adverse effects. The treatment is also aimed at targeting various disease mechanisms that may result in better outcomes. According to the report, the median survival for a person living with pulmonary hypertension is only five to six years. In addition, the current treatments do not target the underlying cause of the disorder. Thus, the disorder treatment is associated with poor patient compliance. Hence, patients often discontinue the treatment without completing the treatment cycle. Other classes (or types) of medications used to treat pulmonary hypertension also have side effects. Therefore, current treatment options result in unmet medical needs that warrant the development of new drugs with better safety and efficacy, thereby driving the market. Further, the report states that patent expiry of drugs such as Revatio is hindering the market growth by allowing low-cost generics to enter the market. Poor patient compliance during treatment due to the adverse effects of the drugs used is also impeding the market growth. Key vendors - Actelion - Bayer - GlaxoSmithKline - United Therapeutics Other prominent vendors - Aires Pharmaceuticals - Arena Pharmaceuticals - Bial - DEKA - Dong-A ST - Gilead - Merck - Northern Therapeutics - Novartis - Pfizer - PhaseBio For more information visit http://www.researchandmarkets.com/research/4ff5rj/pulmonary
UTHR: 148.37 (+2.38), MRK: 53.69 (-0.01), GSK: 40.61 (+0.38), ARNA: 1.73 (+0.03), NVS: 87.65 (+0.60)
SteadyMed Reports Recent Developments and Third Quarter 2015 Financial Results
GlobeNewswire - Thu Nov 12, 3:10PM CST
SteadyMed Ltd. (Nasdaq:STDY), a specialty pharmaceutical company focused on the development of drug products to treat orphan and high-value diseases with unmet parenteral delivery needs, today announced recent developments and financial results for the third quarter ended September 30, 2015.
UTHR: 148.37 (+2.38), STDY: 3.63 (+0.06)
Global United Therapeutics Corporation Market to 2015,Analysis,Competitive Strategies and Forecasts,- Acute Market Reports
M2 - Thu Nov 12, 10:33AM CST
Acute Market Reports include new market research report "Global Markets Directs, United Therapeutics Corporation Product Pipeline Review 2015, provides an overview of the United Therapeutics Corporations pharmaceutical research and development focus " to its huge collection of research reports.
UTHR: 148.37 (+2.38)
12.5% Return Seen to Date on SmarTrend United Therapeutics Call (UTHR)
Comtex SmarTrend(R) - Wed Nov 11, 9:39AM CST
SmarTrend identified an Uptrend for United Therapeutics (NASDAQ:UTHR) on October 27th, 2015 at $138.63. In approximately 2 weeks, United Therapeutics has returned 12.53% as of today's recent price of $156.00.
UTHR: 148.37 (+2.38)
United Therapeutics Stock: What is the Social Media Crowd Thinking About UTHR?
Zacks Equity Research - Zacks Investment Research - Wed Nov 11, 5:04AM CST
If you are looking for a stock in the Medical-Drugs industry, United Therapeutics Corporation (UTHR) could be one to watch closely
UTHR: 148.37 (+2.38)
United Therapeutics Corporation Product Pipeline Review 2015
M2 - Tue Nov 10, 3:19AM CST
AcuteMarketReports.com has announced the addition of " United Therapeutics Corporation - Product Pipeline Review - 2015 " Market Research Report to their Database.
UTHR: 148.37 (+2.38)
Gilead and 2 Biotech Picks Value Investors Will Love
Zacks Equity Research - Zacks Investment Research - Fri Nov 06, 4:07PM CST
Don't miss these value biotech stocks for your portfolio.
BIIB: 280.99 (-2.54), ESRX: 84.25 (-0.41), GILD: 104.55 (+0.74), SHPG: 211.23 (+4.22), UTHR: 148.37 (+2.38), AMGN: 158.11 (+3.61), ANIK: 41.66 (-0.17)
Anthrax - Pipeline Review, H2 2015
M2 - Fri Nov 06, 8:26AM CST
Research and Markets (http://www.researchandmarkets.com/research/3bjw94/anthrax) has announced the addition of the "Anthrax - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Anthrax, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Anthrax and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Aduro BioTech, Inc. - Altimmune, Inc. - Aphios Corporation - Aradigm Corporation - Bavarian Nordic A/S - Bristol-Myers Squibb Company - Cellceutix Corporation - ContraFect Corporation - Dynavax Technologies Corporation - Elusys Therapeutics, Inc. - Emergent BioSolutions Inc. - Green Cross Corporation - Grifols, S.A. - Hawaii Biotech, Inc. - iBio, Inc. - Innovative Biologics, Inc. - Microbiotix, Inc. - NanoBio Corporation - Oragenics, Inc. - PaxVax - Pfenex Inc. - PharmAthene, Inc. - Protein Potential, LLC - ProThera Biologics, LLC. - PsiOxus Therapeutics Limited - Soligenix, Inc. - Syntiron LLC - Tetraphase Pharmaceuticals Inc. - United Therapeutics Corporation - VLP Biotech, Inc. For more information visit http://www.researchandmarkets.com/research/3bjw94/anthrax
DVAX: 24.31 (+0.39), TTPH: 10.94 (-0.19), ADRO: 28.77 (+1.14), EBS: 36.60 (+0.63), UTHR: 148.37 (+2.38), BMY: 65.71 (+0.69), PFNX: 13.72 (-0.64), PIP: 1.71 (unch), IBIO: 0.65 (-0.02), OGEN: 1.30 (unch)
United Therapeutics Corporation 2015 - Market Size, Growth, and Forecasts,Acute Market Reports
M2 - Wed Nov 04, 5:07AM CST
Product Synopsis
UTHR: 148.37 (+2.38)
Global Biosimilars Market Report, 2015-2025 - The biosimilar market is projected to be worth USD 32 billion worldwide by 2025
PR Newswire Europe - Tue Nov 03, 11:11AM CST
Research and Markets (http://www.researchandmarkets.com/research/hcv3cc/global [http://www.researchandmarkets.com/research/hcv3cc/global]) has announced the addition of the "Global Biosimilars Market, 2015 - 2025" [http://www.researchandmarkets.com/research/hcv3cc/global] report to their offering.
BIIB: 280.99 (-2.54), UTHR: 148.37 (+2.38), CTIC: 1.10 (-0.02), CHRS: 27.35 (+0.37), JNJ: 101.40 (+0.18), NPSP: 45.97 (+0.01), IBIO: 0.65 (-0.02), EBS: 36.60 (+0.63), SLXP: 172.96 (+0.15), AMGN: 158.09 (+3.59), SPPI: 5.21 (+0.06), LLY: 81.22 (-0.01), GSK: 40.61 (+0.38), ANIK: 41.66 (-0.17), NVO: 53.93 (+0.67), BAX: 37.63 (-0.30), MRK: 53.69 (-0.01), NVS: 87.65 (+0.60)
Bloomberg's "The Year Ahead: 2016" to Feature Apple's Angela Ahrendts, Bank Of America's Brian Moynihan, Credit Suisse's Tidjane Thiam, Fashion Legend Diane von Furstenberg and More
PR Newswire - Mon Nov 02, 8:00AM CST
Bloomberg today announced the third annual "The Year Ahead: 2016" Summit, an intimate gathering of today's most powerful business leaders and industry influencers from around the world on November 9-10th in New York City. Providing forward-looking insight on the industries, companies, products, people, and trends poised to emerge over the course of next year, "The Year Ahead: 2016" is designed to help global executives get ahead of the challenges their businesses will face in the months to come. Speakers include Apple Senior Vice President Angela Ahrendts; Bank of America Chairman and CEO Brian Moynihan; Credit Suisse CEO Tidjane Thiam; BBG Ventures President Susan Lyne; United Therapeutics Chairman and Co-CEO Martine Rothblatt; and Jet.com Founder and CEO Marc Lore.
UTHR: 148.37 (+2.38)
United Therapeutics Beats on Q3 Earnings, Revenues
Arpita Dutt - Zacks Investment Research - Wed Oct 28, 11:18AM CDT
United Therapeutics' (UTHR) third quarter results were better-than-expected with the company's products performing well.
MDT: 76.51 (+0.27), UTHR: 148.37 (+2.38), AMGN: 158.13 (+3.63), EXEL: 5.66 (+0.18)
United Therapeutics (UTHR) Catches Eye: Stock Jumps 8.8%
Zacks Equity Research - Zacks Investment Research - Wed Oct 28, 7:45AM CDT
United Therapeutics Corporation (UTHR) was a big mover last session, as the company saw its shares rise roughly 9% on the day.
LCI: 36.23 (+0.86), UTHR: 148.37 (+2.38)
SmarTrend Watching for Potential Pullback in Shares of United Therapeutics After 8.78% Gain
Comtex SmarTrend(R) - Tue Oct 27, 4:38PM CDT
United Therapeutics (NASDAQ:UTHR) traded in a range yesterday that spanned from a low of $134.27 to a high of $142.98. Yesterday, the shares gained 8.8%, which took the trading range above the 3-day high of $129.90 on volume of 1.9 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
UTHR: 148.37 (+2.38)
United Therapeutics Rises 8.78% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Tue Oct 27, 4:38PM CDT
United Therapeutics (NASDAQ:UTHR) traded in a range yesterday that spanned from a low of $134.27 to a high of $142.98. Yesterday, the shares gained 8.8%, which took the trading range above the 3-day high of $129.90 on volume of 1.9 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
UTHR: 148.37 (+2.38)
UNITED THERAPEUTICS CORP (UTHR) Earnings Report: Q3 2015 Conference Call Transcript
at The Street - Tue Oct 27, 1:46PM CDT
The following UNITED THERAPEUTICS CORP (UTHR) conference call took place on October 27, 2015, 09:00 AM ET. This is a transcript of that earnings call:
UTHR: 148.37 (+2.38)
4 Drugmakers Who Beat Q3 Estimates Tuesday
at Investor's Business Daily - Tue Oct 27, 11:30AM CDT
The battered drug industry got a blast of good news Tuesday morning as three big pharmas and one sizable biotech beat Wall Street's Q3 expectations, sending their stocks up. United Therapeutics (UTHR) was up 11% in midday trading on the stock market...
GILD: 104.55 (+0.74), MRK: 53.69 (-0.01), PFE: 33.05 (-0.11), UTHR: 148.37 (+2.38), ABBV: 60.39 (+0.38), BMY: 65.71 (+0.69)
United Therapeutics tops Street 3Q forecasts
Automated Insights - Tue Oct 27, 5:15AM CDT
SILVER SPRING, Md. (AP) _ United Therapeutics Corp. (UTHR) on Tuesday reported third-quarter net income of $464.4 million, after reporting a loss in the same period a year earlier.
UTHR: 148.37 (+2.38)
United Therapeutics Corporation Reports Third Quarter 2015 Financial Results
PR Newswire - Tue Oct 27, 5:00AM CDT
United Therapeutics Corporation (NASDAQ: UTHR) today announced its financial results for the third quarter ended September 30, 2015.
UTHR: 148.37 (+2.38)
United Therapeutics Has Returned 26.0% Since SmarTrend Recommendation (UTHR)
Comtex SmarTrend(R) - Wed Oct 21, 4:50PM CDT
SmarTrend identified a Downtrend for United Therapeutics (NASDAQ:UTHR) on July 27th, 2015 at $166.73. In approximately 3 months, United Therapeutics has returned 26.02% as of today's recent price of $123.35.
UTHR: 148.37 (+2.38)
Pulmonary Hypertension - Global Market Research 2015-2019 - Increased focus on combination therapies
M2 - Wed Oct 21, 10:01AM CDT
Research and Markets (http://www.researchandmarkets.com/research/4ff5rj/pulmonary) has announced the addition of the "Pulmonary Hypertension - Global Market Research 2015-2019" report to their offering. The global pulmonary hypertension market to grow at a CAGR of 2.92% over the period 2014-2019. The report, Global Pulmonary Hypertension Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. It covers the market size and forecast as well as market segmentation and pipeline landscape. The report includes a discussion of the key vendors operating in this market. The hypertension treatment is shifting toward the use of combination therapies that employ two or more drugs. Combination therapy with separate agents or a fixed-dose combination pill offers the potential to lower blood pressure at a faster pace, help in obtaining target blood pressure, and decrease adverse effects. The treatment is also aimed at targeting various disease mechanisms that may result in better outcomes. According to the report, the median survival for a person living with pulmonary hypertension is only five to six years. In addition, the current treatments do not target the underlying cause of the disorder. Thus, the disorder treatment is associated with poor patient compliance. Hence, patients often discontinue the treatment without completing the treatment cycle. Other classes (or types) of medications used to treat pulmonary hypertension also have side effects. Therefore, current treatment options result in unmet medical needs that warrant the development of new drugs with better safety and efficacy, thereby driving the market. Further, the report states that patent expiry of drugs such as Revatio is hindering the market growth by allowing low-cost generics to enter the market. Poor patient compliance during treatment due to the adverse effects of the drugs used is also impeding the market growth. Key vendors - Actelion - Bayer - GlaxoSmithKline - United Therapeutics Other prominent vendors - Aires Pharmaceuticals - Arena Pharmaceuticals - Bial - DEKA - Dong-A ST - Gilead - Merck - Northern Therapeutics - Novartis - Pfizer - PhaseBio For more information visit http://www.researchandmarkets.com/research/4ff5rj/pulmonary
UTHR: 148.37 (+2.38), MRK: 53.69 (-0.01), GSK: 40.61 (+0.38), ARNA: 1.73 (+0.03), NVS: 87.65 (+0.60)
